Early Covid Treatment Symposium - Question #4

Question #4: Why is it acceptable to use remdesivir to treat COVID-19, but not ivermectin? Can you provide evidence to support the safety and efficacy of remdesivir over the safety and efficacy of ivermectin?
______

Bringing together thought leaders in the healthcare field to evaluate and broaden opportunities to prevent suffering and death from the Covid-19 virus. The University of Kansas Health System turned down an invitation to participate in the roundtable discussion.

Speakers:
Dr. Peter McCullough
Dr. Pierre Kory
Dr. John Littell
Dr. Jesse Lopez

Resources:
COVID-19 Treatments: https://www.kshf.org/treatments
Timeline of HCQ and IVM: https://www.kshf.org/timeline